Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Innoviva, Inc. (INVA)

$21.44 +1.13% NASDAQ: INVA · 15-min delayed
  • BURLINGAME, California
  • Public · NASDAQ: INVA
  • 159 employees
$1.7BMarket cap
$411.3MRevenue · FY2025
$4.4MNet income
159Employees
INVANASDAQ
2004IPO

About Innoviva, Inc.

Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2025
$411.3M
Net income
$4.4M
Total assets
$1.6B
Market cap
$1.7B
Gross margin
74.8%
Operating margin
39.8%
Net margin
65.9%

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2025

Financial statements

Income statement

Revenue
$411.3M
Cost of revenue
$103.7M
Gross profit
$307.7M
Operating expenses
$143.9M
Operating income
$163.7M
Income tax
$55.7M
Net income
$271.2M
EPS (basic)
$4.02
EPS (diluted)
$3.30

Balance sheet

Total assets
$1.6B
Current assets
$727.5M
Total liabilities
$462.3M
Current liabilities
$49.7M
Shareholders’ equity
$1.2B

Cash flow

Operating cash flow
$196.9M
Investing cash flow
$40.5M
Financing cash flow
$8.6M
Net cash flow
$246.0M

Statements via Polygon.io (SEC filings)

NASDAQ: INVA
$21.44 +1.13%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$16.67 $24.24

52-week range

Market cap
$1.7B
P/E ratio
6.5
EPS (diluted)
$3.3
Dividend yield
4.66%
Shares outstanding
77.5M
Open
Day range
Prev close
Volume
IPO date
Oct 5, 2004

Innoviva, Inc. (INVA) Stock Price

  • Profitable — net income of $4.4M in FY2025.
  • Revenue grew 5% from FY2021 to FY2025.
  • Gross margin of 74.8%, net margin 65.9%.
  • Trading 12% below its 52-week high.
  • Pays a dividend yielding about 4.66% annually.
  • Valued at a price-to-earnings (P/E) ratio of 6.5.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Innoviva, Inc..

Write a review
Newsroom

News about Innoviva, Inc.

News & sentiment via Polygon.io

FAQ

Innoviva, Inc.: frequently asked questions

Is Innoviva, Inc. an American company?

Innoviva, Inc. is a US-based company headquartered in Burlingame, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Innoviva, Inc. headquartered?

Innoviva, Inc. is headquartered in Burlingame, California, United States.

Is Innoviva, Inc. publicly traded?

Yes — Innoviva, Inc. is a publicly traded company. Its stock trades under the ticker symbol INVA on the NASDAQ.

What does Innoviva, Inc. do?

Innoviva, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →